CD8A and neoplasm: CXCL1 and CCL519 have been shown to recruit conventional type 1 dendritic cells (cDC1 cells) for the activation of antitumor immune cells; similarly, CXCL9 and CXCL10 have been reported to recruit CD8+ effector T cells (CD8+ Teff cells) to shape a tumor-immunoactivated TME 20.